BR112012022868A2 - morfolinilquinazolinas - Google Patents
morfolinilquinazolinasInfo
- Publication number
- BR112012022868A2 BR112012022868A2 BR112012022868-4A BR112012022868A BR112012022868A2 BR 112012022868 A2 BR112012022868 A2 BR 112012022868A2 BR 112012022868 A BR112012022868 A BR 112012022868A BR 112012022868 A2 BR112012022868 A2 BR 112012022868A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- formula
- relates
- halet
- formulas
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
morfolinilquinazolinas. a invenção refere-se aos compostos das fórmulas (i), (ii) e (iii), em que r1, r2, r3, r4, y, w1, w2, l, a, alk, cyc, ar, het^ 1^, het^ 2^, hal e n têm significado declarado na reivindicação 1, e/ou sais fisiologicamente inofensivos, tautômeros e estereoisômeros dos mesmos, incluindo suas misturas em todas as razões. os compostos da fórmula (i) podem ser usados para inibir as proteínas serina-treonina cinases e também para sensibilizar células cancerosas aos anticarcinógenos e/ou radiação ionizante. a invenção também refere-se ao uso dos compostos da fórmula (i) em profilaxia, terapia ou controle do progresso de câncer, tumores, metástase ou distúrbios angiogênicos, em combinação com radioterapia e/ou um anticarcinógeno. a invenção ainda refere-se a um método para produzir os compostos da fórmula (i) reagindo os compostos das fórmulas (ii) e (iii) e opcionalmente convertendo uma base ou ácido dos compostos da fórmula (i) em um de seus sais.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102010011493.6 | 2010-03-16 | ||
DE102010011493 | 2010-03-16 | ||
PCT/EP2011/000767 WO2011113512A1 (de) | 2010-03-16 | 2011-02-17 | Morpholinylchinazoline |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012022868A2 true BR112012022868A2 (pt) | 2018-06-05 |
Family
ID=43828057
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012022868-4A BR112012022868A2 (pt) | 2010-03-16 | 2011-02-17 | morfolinilquinazolinas |
Country Status (16)
Country | Link |
---|---|
US (1) | US9126952B2 (pt) |
EP (1) | EP2547664B1 (pt) |
JP (1) | JP2013522249A (pt) |
KR (1) | KR20130017086A (pt) |
CN (1) | CN102803227B (pt) |
AR (1) | AR080757A1 (pt) |
AU (1) | AU2011229542A1 (pt) |
BR (1) | BR112012022868A2 (pt) |
CA (1) | CA2793299A1 (pt) |
EA (1) | EA201201289A1 (pt) |
ES (1) | ES2586227T3 (pt) |
IL (1) | IL221901A (pt) |
MX (1) | MX2012010557A (pt) |
SG (1) | SG183855A1 (pt) |
WO (1) | WO2011113512A1 (pt) |
ZA (1) | ZA201207727B (pt) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102011118830A1 (de) * | 2011-11-18 | 2013-05-23 | Merck Patent Gmbh | Morpholinylbenzotriazine |
SG10201704095UA (en) | 2012-04-24 | 2017-06-29 | Vertex Pharma | Dna-pk inhibitors |
LT2970218T (lt) | 2013-03-12 | 2019-03-12 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitoriai |
UY35464A (es) | 2013-03-15 | 2014-10-31 | Araxes Pharma Llc | Inhibidores covalentes de kras g12c. |
DE102013008118A1 (de) * | 2013-05-11 | 2014-11-13 | Merck Patent Gmbh | Arylchinazoline |
UA119971C2 (uk) * | 2013-10-10 | 2019-09-10 | Араксіс Фарма Ллк | Інгібітори g12c kras |
JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
RU2675270C2 (ru) | 2013-10-17 | 2018-12-18 | Вертекс Фармасьютикалз Инкорпорейтед | Сокристаллы и содержащие их фармацевтические композиции |
JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
US10011600B2 (en) | 2014-09-25 | 2018-07-03 | Araxes Pharma Llc | Methods and compositions for inhibition of Ras |
PT3560924T (pt) * | 2015-04-02 | 2021-07-02 | Merck Patent Gmbh | Imidazolinilquinolinas e a sua utilização como inibidores da cinase atm |
EA201792214A1 (ru) | 2015-04-10 | 2018-01-31 | Араксис Фарма Ллк | Соединения замещенного хиназолина |
US10428064B2 (en) | 2015-04-15 | 2019-10-01 | Araxes Pharma Llc | Fused-tricyclic inhibitors of KRAS and methods of use thereof |
US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
WO2017058768A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
WO2017058915A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
EP3356353A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
WO2017058807A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
EP3356339A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
US10882847B2 (en) | 2015-09-28 | 2021-01-05 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
WO2017058805A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
WO2017070256A2 (en) | 2015-10-19 | 2017-04-27 | Araxes Pharma Llc | Method for screening inhibitors of ras |
KR20180081596A (ko) | 2015-11-16 | 2018-07-16 | 아락세스 파마 엘엘씨 | 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법 |
WO2017100546A1 (en) | 2015-12-09 | 2017-06-15 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
RU2758669C2 (ru) | 2016-09-27 | 2021-11-01 | Вертекс Фармасьютикалз Инкорпорейтед | Способ лечения рака с применением сочетания днк-поражающих агентов и ингибиторов днк-пк |
US10280172B2 (en) | 2016-09-29 | 2019-05-07 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
US10377743B2 (en) | 2016-10-07 | 2019-08-13 | Araxes Pharma Llc | Inhibitors of RAS and methods of use thereof |
US11279689B2 (en) | 2017-01-26 | 2022-03-22 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer |
WO2018140599A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
CN110382482A (zh) | 2017-01-26 | 2019-10-25 | 亚瑞克西斯制药公司 | 稠合的杂-杂二环化合物及其使用方法 |
WO2018140512A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
WO2018140514A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
WO2018218069A1 (en) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant kras, hras or nras |
TW201906832A (zh) | 2017-05-25 | 2019-02-16 | 美商亞瑞克西斯製藥公司 | 用於癌症治療之化合物及其使用方法 |
MX2019013954A (es) | 2017-05-25 | 2020-08-31 | Araxes Pharma Llc | Inhibidores covalentes de kras. |
DK3551188T3 (da) | 2017-10-31 | 2024-01-08 | Southern Res Inst | Substituerede quinazolinsulfonamider som hæmmere af thioredoxin-interagerende protein (txnip) |
US20220073475A1 (en) | 2019-01-17 | 2022-03-10 | Universite De Lille | 5-membered heteroaryl compounds containing a hydroxamate moiety and their use |
CN111909144A (zh) * | 2019-05-10 | 2020-11-10 | 山东轩竹医药科技有限公司 | 喹唑啉类dna-pk抑制剂 |
TW202208355A (zh) | 2020-05-04 | 2022-03-01 | 美商安進公司 | 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法 |
BR112022022338A2 (pt) | 2020-05-04 | 2023-01-10 | Amgen Inc | Compostos heterocíclicos como receptor desencadeador expresso em agonistas de células mieloides 2 e métodos de uso |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR930702292A (ko) | 1990-11-06 | 1993-09-08 | 알렌 제이. 스피겔 | 종양 치료 활성을 증대시키기 위한 퀴나졸린 유도체 |
GB9300059D0 (en) * | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
JP2994165B2 (ja) * | 1992-06-26 | 1999-12-27 | ゼネカ・リミテッド | キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤 |
GB9707800D0 (en) * | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
WO2000061186A1 (en) | 1999-04-08 | 2000-10-19 | Arch Development Corporation | Use of anti-vegf antibody to enhance radiation in cancer therapy |
US7179912B2 (en) * | 2000-09-01 | 2007-02-20 | Icos Corporation | Materials and methods to potentiate cancer treatment |
CA2442742A1 (en) * | 2001-02-21 | 2002-08-29 | Mitsubishi Pharma Corporation | Quinazoline derivatives |
CN1849122A (zh) * | 2001-12-03 | 2006-10-18 | 先灵公司 | Fpt抑制剂与至少两种抗肿瘤药在治疗癌症中的用途 |
PE20060285A1 (es) * | 2004-03-30 | 2006-05-08 | Aventis Pharma Inc | Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp) |
ES2288359B1 (es) | 2005-07-08 | 2009-07-23 | Consejo Superior Investigaciones Cientificas | Sistema de control coordinado para lineas de extraccion continua de aceite de oliva virgen. |
JP2009510044A (ja) * | 2005-09-29 | 2009-03-12 | グラクソ グループ リミテッド | ピラゾロ[3,4−b]ピリジン化合物及びそのPDE4阻害薬としての使用 |
DE102006012251A1 (de) | 2006-03-15 | 2007-11-08 | Grünenthal GmbH | Substituierte 4-Amino-chinazolin-Derivate und ihre Verwendung zur Herstellung von Arzneimitteln |
EP1903038A1 (de) * | 2006-09-07 | 2008-03-26 | Bayer Schering Pharma Aktiengesellschaft | N-(1-Hetaryl-piperidin-4-yl)-(het)arylamide als EP2-Rezeptor Modulatoren |
ES2340640T3 (es) * | 2007-03-23 | 2010-06-07 | Icagen, Inc. | Inhibidores de canales de iones. |
CA2693901C (en) * | 2007-07-20 | 2015-12-29 | Nerviano Medical Sciences S.R.L. | Substituted indazole derivatives active as kinase inhibitors |
WO2009020140A1 (ja) * | 2007-08-06 | 2009-02-12 | Dainippon Sumitomo Pharma Co., Ltd. | アダマンチルウレア誘導体 |
EP2318377B1 (en) * | 2008-07-31 | 2013-08-21 | Genentech, Inc. | Pyrimidine compounds, compositions and methods of use |
CN102884062B (zh) * | 2009-12-23 | 2016-08-03 | 嘉世高制药公司 | 氨基嘧啶激酶抑制剂 |
-
2011
- 2011-02-17 US US13/581,699 patent/US9126952B2/en active Active
- 2011-02-17 KR KR20127026875A patent/KR20130017086A/ko not_active Application Discontinuation
- 2011-02-17 CA CA 2793299 patent/CA2793299A1/en not_active Abandoned
- 2011-02-17 MX MX2012010557A patent/MX2012010557A/es not_active Application Discontinuation
- 2011-02-17 JP JP2012557426A patent/JP2013522249A/ja active Pending
- 2011-02-17 ES ES11704552.6T patent/ES2586227T3/es active Active
- 2011-02-17 BR BR112012022868-4A patent/BR112012022868A2/pt not_active IP Right Cessation
- 2011-02-17 CN CN201180014341.9A patent/CN102803227B/zh not_active Expired - Fee Related
- 2011-02-17 EP EP11704552.6A patent/EP2547664B1/de active Active
- 2011-02-17 AU AU2011229542A patent/AU2011229542A1/en not_active Abandoned
- 2011-02-17 WO PCT/EP2011/000767 patent/WO2011113512A1/de active Application Filing
- 2011-02-17 EA EA201201289A patent/EA201201289A1/ru unknown
- 2011-02-17 SG SG2012064788A patent/SG183855A1/en unknown
- 2011-03-16 AR ARP110100836 patent/AR080757A1/es unknown
-
2012
- 2012-09-11 IL IL221901A patent/IL221901A/en not_active IP Right Cessation
- 2012-10-15 ZA ZA2012/07727A patent/ZA201207727B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2547664B1 (de) | 2016-05-04 |
CN102803227B (zh) | 2016-01-20 |
ZA201207727B (en) | 2013-06-26 |
AR080757A1 (es) | 2012-05-09 |
SG183855A1 (en) | 2012-10-30 |
IL221901A (en) | 2016-04-21 |
CA2793299A1 (en) | 2011-09-22 |
JP2013522249A (ja) | 2013-06-13 |
US9126952B2 (en) | 2015-09-08 |
US20130012489A1 (en) | 2013-01-10 |
MX2012010557A (es) | 2012-10-05 |
EA201201289A1 (ru) | 2013-08-30 |
KR20130017086A (ko) | 2013-02-19 |
IL221901A0 (en) | 2012-12-02 |
ES2586227T3 (es) | 2016-10-13 |
CN102803227A (zh) | 2012-11-28 |
EP2547664A1 (de) | 2013-01-23 |
AU2011229542A1 (en) | 2012-11-08 |
WO2011113512A1 (de) | 2011-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012022868A2 (pt) | morfolinilquinazolinas | |
BR112014011805A2 (pt) | morfolinilbenzotriazinas para uso em terapia de câncer | |
BR112013004613A2 (pt) | imidazo{4,5-c]quinolinas como inibidores de dna-pk | |
CY1124117T1 (el) | Ετεροκυκλικες αλκυνυλοβενζολικες ενωσεις και ιατρικες συνθεσεις και χρησεις αυτων | |
BR112015018751A2 (pt) | derivados de piridazinona macrocíclicos | |
BRPI0919873B8 (pt) | compostos de pirazol[1,5-a]pirimidina substituídos como inibidores da trk quinase, seus processos de preparação e composições farmacêuticas | |
BR112017011798A2 (pt) | 4,6-substituído-pirazolo[1,5-a] pirazinas como inibidores janus cinase | |
BR112012031561A2 (pt) | morfolino pirimidinas e seu uso em terapia. | |
BR112015021549A2 (pt) | inibidores de piridina cinase cdk9 | |
BR112014007694A2 (pt) | 1-pirazolil-3-(4-((2-anilinopirimidin-4-il)óxi)naftaleno-1-il)ureias como inibidores de p38 map cinase | |
BR112015028501B8 (pt) | Compostos derivados de bipirazol, seus sais, composição compreendendo o composto ou o sal, método de inibição in vitro de uma atividade de jak1, e processo de preparação de sal de ácido fosfórico | |
CY1117352T1 (el) | Υποκατεστημενες ιμιδαζοπυριδαζiνες | |
BR112012020693A8 (pt) | Derivados de ciclobutano e metilciclobutano como inibidores de janus quinase e composição que os compreende | |
BR112015018663A2 (pt) | derivados de piridazinona-amidas | |
BR112015012366A8 (pt) | antagonistas de cxcr7, uso dos mesmos, composição farmacêutica, bem como métodos para detectar níveis elevados de cxcr7 em uma amostra e para imagear um tumor, órgão, ou tecido | |
BR112015026819A2 (pt) | composto de diamino-pirimidina deuterada, método para preparar uma composição farmacêutica, composição farmacêutica, uso de um composto, método para preparar um composto e intermediário | |
BR112018007772A2 (pt) | compostos de imidazo[4,5-c]quinolin-2-ona e seu uso no tratamento do câncer | |
BR112013001088A2 (pt) | "derivados substituídos como inibidores a quinase de imidazoquinolina" | |
BR112012000209B8 (pt) | heterodímeros de ácido glutâmico e seus processos de preparação | |
BR112015023412A8 (pt) | 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante, sua composição farmacêutica e seu uso. | |
BR112015027319A8 (pt) | Métodos e composições para modular a expressão de apolipoproteína (a) | |
EA201100030A1 (ru) | Пиразольные соединения 436 | |
EA201070395A1 (ru) | Ингибиторы polo-подобных киназ | |
BRPI0808888B8 (pt) | composto de fenil amino pirimidina para uso no tratamento de uma doença associada à quinase, processo para a preparação do composto, composição farmacêutica, e, implante | |
EA201071232A1 (ru) | Триазины как ингибиторы киназы pi3 и mtor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2475 DE 12-06-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |